About Author

Chengdu Kaijie Biopharm Co, Ltd. (KJBP) is one of leading peptide manufacturers in Asia. With its highest capacity of production in China and the outstanding quality of peptide products, Kaijie holds a unique position.

Thymopentin

1.1.A Intra-articular route

1) In rheumatoid arthritis patients, thymopentin has been given intra-articularly (knee joints) in doses of 50 milligrams once weekly for 4 weeks

1.1.B Intramuscular route

1) Following primary chemotherapy, treatment with thymopentin 50 milligrams/day intramuscularly for 2 weeks, followed by 50 milligrams 3 times a week for 3 doses, has been attempted in OVARIAN CARCINOMA patients (Heine et al, 1991). However, it was not associated with improvements in clinical course or survival time.

2) The recommended dose for the treatment of DIGEORGE SYNDROME or LOUIS-BAR SYNDROME (ATAxia TELANGIECTASIA) is 0.5 to 1
Chengdu KaiJie Biopharm Co., Ltd.
Segment 1, Industrial Road, Dayi county, Chengdu, Sichuan, P. R. China, 611330
Tel: 86-28-88203603, Fax: 86-28-88203605  WEB: www.kjpep.com

milligram/kilogram/day thymopentin intramuscularly or subcutaneously for 2 weeks, followed by 0.5 to 1 milligram/kilogram 2 to 3 times weekly. The duration of therapy should be based on the patient's clinical status and response.

1.1.C Intravenous route
1) For intravenous administration, 0.5 milliliter of a 100-milligram/milliliter solution of thymopentin (50 milligrams) has been diluted in normal saline to a volume of 10 milliliters and given as a slow injection over 10 minutes.
2) In RHEUMATOID ARTHRITIS, usual doses of thymopentin in clinical studies have been 50 milligrams intravenously three times per week. The duration of therapy has usually not exceeded 3 weeks (range, 3 to 6 weeks).
3) Thymopentin in intravenous doses of 50 milligrams three times weekly for 3 weeks has also been used in the treatment of severe ALOPECIA AREATA.

1.1.D Subcutaneous route
1) Subcutaneous thymopentin 50 milligrams three times weekly for a duration of 6 weeks has been administered for the prophylaxis and treatment of recurrent RESPIRATORY TRACT INFECTION (Sundal, 1993b) and treatment of recurrent herpes labialis (Bolla et al, 1985) and HERPES ZOSTER infection.
2) In asymptomatic HUMAN IMMUNODEFICIENCY VIRUS INFECTION, 50 milligrams subcutaneously three times weekly for up to 52 weeks has been given in an effort to slow progression of the disease.
3) For treatment of ATOPIC DERMATITIS in adults, subcutaneous doses of 50 milligrams once daily for 6 weeks have been employed.
4) Combination therapy with chemotherapy and immunotherapy with thymopentin 50 milligrams/day for 2 weeks, followed by 50 milligrams 3 times a week, has been used in the treatment of BREAST CANCER and OVARIAN CANCER. It is suggested that thymopentin may reduce the immunosuppressive side effects of antineoplastic agents.
5) In a small study, thymopentin 100 milligrams subcutaneously 1 to 3 times weekly for 11 to 289 weeks had some beneficial effects in the treatment of chronic hepatitis B.

2) The recommended dose for the treatment of DiGeorge syndrome or Louis-Bar syndrome (ataxia telangiectasia) is 0.5 to 1 milligram/kilogram/day thymopentin intramuscularly or subcutaneously for 2 weeks, followed by 0.5 to 1 milligram/kilogram 2 to 3 times weekly. The duration of therapy should be based on the patient's clinical status and response.

2. Pediatric Dosage
2.1.A Intra-articular route

Chengdu KaiJie Biopharm Co., Ltd. is dedicated to be the leading peptide manufacturer in Asia.
www.kjpep.com  sales@kjpep.com
1) In children with monoarticular-onset JUVENILE CHRONIC ARTHRITIS (monoarthritis of the knee), thymopentin has been administered intraarticularly in doses of 1 milligram/kilogram weekly for 10 weeks.

2.1.B Intravenous route

1) Intravenous doses of thymopentin 1 milligram/kilogram three times weekly for the first 3 weeks, then once weekly for 3 subsequent weeks, have been given to children with systemic-onset juvenile chronic arthritis. In responding patients, the drug was continued as maintenance therapy in doses of 1 milligram/kilogram every 2 weeks for up to 34 months. The dose of thymopentin was diluted with normal saline to a 10-milliliter volume and injected over a period of 10 minutes.

2.1.C Subcutaneous route

1) Thymopentin 1 milligram/kilogram subcutaneously for 3 consecutive days, then twice weekly for 5 weeks, has been used in the treatment of recurrent RESPIRATORY TRACT INFECTIONS in children (1 to 12 years of age).

2) For treatment of ATOPIC DERMATITIS in children (over 2 years of age), subcutaneous doses of 50 milligrams once daily or three times weekly for 6 weeks have been employed.